The role of prophylactic cranial irradiation (PCI) in metastatic small-cell lung cancer (SCLC) is controversial. Using the National Cancer Database we show that patients treated with PCI have improved survival outcomes. In light of conflicting randomized trials, this study adds information to help guide physician and patient decision-making about the utility of PCI in metastatic SCLC. Introduction: Patients with small-cell lung cancer (SCLC) have a high incidence of occult brain metastases and are often treated with prophylactic cranial irradiation (PCI). Despite a small survival advantage in some studies, the role of PCI in extensive stage SCLC remains controversial. We used the National Cancer Database to assess survival of patients with metastatic SCLC treated with PCI. Patients and Methods: Metastatic SCLC patients without brain metastases were identified. To minimize treatment selection bias, patients with an overall survival (OS) < 6 months were excluded. Cox regression identified variables associated with OS. Patients were propensity score-matched on factors associated with receipt of PCI or OS. The effect of PCI on OS was examined using KaplaneMeier estimates. Results: In the overall cohort (n ¼ 4257), treatment with PCI (n ¼ 473) was associated with improved survival (hazard ratio, 0.66; 95% confidence interval, 0.60-0.74; P < .0001). Comparisons of propensity score-matched cohorts revealed a significant survival benefit for patients who received PCI in median OS (13.9 vs. 11.1 months; P < .0001), as well as 1-and 2-year OS (61.2% vs. 44.0% and 19.8% vs. 11.5%, respectively; P < .0001). This survival benefit persisted even after excluding patients who survived < 9 months (median: 15.3 vs. 12.9 months; P < .0001). In multivariable analysis, predictors of receipt of PCI were Caucasian race, younger age, and lower CharlsoneDeyo score. Conclusion: Using a modern population-based data set, we showed that metastatic SCLC patients treated with PCI have significantly improved OS. This large retrospective study helps address the conflicting prospective data.
Introduction
Small-cell lung cancer (SCLC) comprises approximately 13% of all new lung cancer diagnoses with approximately 31,000 cases annually in the United States.
1,2 SCLC is characterized by its aggressive nature, rapid doubling time, and high metastatic potential. Most patients (60%-70%) present with disseminated, extensive-stage (ES) disease at diagnosis, for which the primary treatment is chemotherapy. 3, 4 Small-cell lung cancer has a notoriously high rate of brain metastases, with > 50% of patients developing intracranial involvement over the course of their disease. 5, 6 As a result, for patients who respond well to initial chemotherapy, prophylactic cranial irradiation (PCI) is used to decrease the risk of brain metastases and the associated neurological morbidity of intracranial progression as shown in multiple meta-analyses. [7] [8] [9] In patients with limited-stage disease, there is evidence that PCI decreases the risk of brain metastases and improves survival. 8, 9 Therefore, the National category 1 recommendation to offer PCI in patients with limitedstage SCLC who respond to initial therapy. 3 In patients with ES disease, PCI also decreases the risk of developing symptomatic brain metastases, 10, 11 but its effect on overall survival (OS) is controversial. PCI appeared to offer a survival benefit in one randomized trial of patients with ES disease who responded to chemotherapy. 10 However, this trial has been criticized, because patients were not screened for brain metastases with brain imaging before PCI unless they had neurological symptoms. As a result, some patients likely had brain metastases at the time of PCI and might have achieved a survival benefit through the treatment of known intracranial disease. Per current NCCN guidelines, PCI is generally reserved for patients with an objective clinical or radiographic response to chemotherapy and negative postchemotherapy brain imaging. 3 Interestingly, the results of another recent phase III trial reported that ES-SCLC patients who responded to initial chemotherapy and had a negative brain magnetic resonance imaging (MRI) scan did not have a survival benefit when treated with PCI.
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Because of the disparate results of prospective trials on the role of PCI in ES-SCLC and the low likelihood that additional randomized studies will be performed, we undertook this study to better understand the clinical effect of PCI on survival outcomes using a modern, population-based database at the national level. Although we recognize that prospective randomized controlled trials are the gold standard, we hope that this study adds clinically meaningful data to an area of controversy. We assessed clinical outcomes using the National Cancer Database (NCDB) and propensity scorematching to better elucidate the potential benefits of PCI in patients with ES-SCLC and to help direct the clinical management of these patients. We hypothesized that PCI would confer an OS benefit in patients with ES-SCLC without brain metastases who respond to standard chemotherapy.
Patients and Methods

Data Source
After obtaining approval from our institutional review board, we conducted a propensity score-matched cohort study using the NCDB. The NCDB is a large national oncology registry sponsored by the American College of Surgeons and the American Cancer Society encompassing > 1500 Commission on Cancer (CoC) institutions. Approximately 70% of new nationwide cancer diagnoses are recorded in this database. 12 
Patient Selection
Patients with metastatic SCLC without brain metastases treated with chemotherapy between 2010 and 2012 were identified in the NCDB. Of note, the study period commenced in 2010 when the NCDB began recording the presence of brain metastases and ended in 2012 to allow for adequate follow-up and survival data to perform risk-adjusted survival analysis. Patients were excluded if they had nonmetastatic disease, known brain metastases, or unknown intracranial disease status, underwent surgery, received doses of whole brain radiation (WBRT) outside the typical prophylactic dose range (< 20 Gy or 30 Gy), or did not receive chemotherapy (Figure 1 ). To account for bias of delivery of PCI, patients with an OS < 6 months were excluded to eliminate those who likely did not respond to or relapsed quickly after first-line chemotherapy, and thus would not be optimal candidates for PCI. We also conducted the same analysis including all patients without a minimum survival cutoff.
Definition of PCI
To exclude patients who received therapeutic WBRT, receipt of PCI was defined as those patients with nonintracranial metastatic SCLC at diagnosis who received WBRT to a dose consistent with standard PCI doses of 20 Gy and < 30 Gy.
End Points
The primary outcome was the effect of PCI on patient OS in metastatic SCLC. Overall survival was defined as the interval between diagnosis and date of death or last follow-up visit. In addition, patient, clinical, and demographic factors associated with receipt of PCI were identified.
Independent Variables
Patient characteristics included age at diagnosis, sex, and race. Clinical characteristics incorporated CharlsoneDeyo comorbidity score, primary tumor location, tumor grade, and clinical tumor, node, metastases (TNM) classification. Demographic factors assessed were insurance status, income, and facility type. Facility type was defined as academic or nonacademic-based CoC designation. 13 
Statistical Analysis
Descriptive statistics are presented as frequencies for categorical variables and median (interquartile range) for continuous variables.
Pearson c 2 or Fisher exact tests were used to analyze categorical variables. Predictors of receipt of PCI were examined using univariable and multivariable logistic regression. Multivariable analysis used backward, stepwise logistic regression (P .05 for entry; P > .10 for removal). OS was analyzed using univariable and multivariable Cox proportional hazards modeling. The multivariable Cox regression used backward stepwise selection (P .05 for entry; P > .10 for removal).
Using a minimum OS cutoff of 6 months, propensity scores were developed accounting for factors significantly associated with either receipt of PCI or OS in multivariable analysis. These variables included age, sex, race, CharlsoneDeyo score, insurance type, income, facility type, clinical T classification, clinical N classification, and clinical M classification. Patients were then paired 1:1 on these propensity scores using the "greedy" nearest-neighbor matching algorithm without replacement. Standardized differences were estimated before and after matching to evaluate the balance of covariate; values < 0.1 indicated balance between the treatment groups. After 1:1 propensity score-matching, OS between matched PCI and no PCI cohorts was examined using KaplaneMeier analysis using KleineMoeschberger methodology. 14 To further account for potential biases favoring the receipt of PCI in metastatic SCLC patients with more favorable prognoses, a landmark survival analysis was conducted for patients with a minimum OS of 9 months. We additionally conducted the analysis on the entire patient cohort without a minimum survival cutoff. The same propensity score-matching methodology and cohort comparisons described previously were used. Statistical analyses were completed Clinical Lung Cancer May 2018 -261 using SPSS version 22.0 (IBM Corp, Armonk, NY). Associations were noted as statistically significant at P < .05. All tests were 2-sided.
Results
Characteristics of the Overall, Unmatched Study Population
In the overall cohort of patients with metastatic SCLC without brain metastases who survived at least 6 months (n ¼ 4257), 473 patients (11.1%) received PCI, whereas 3784 patients (88.9%) received only chemotherapy without PCI. Among the patients who received PCI, the most common dose fractionation was 25 Gy in 10 fractions (n ¼ 391; 83%). Baseline characteristics of the cohorts are shown in Table 1 . Before propensity score-matching, the PCI cohort differed significantly from the no PCI group on the basis of age, race, CharlsoneDeyo comorbidity score, and insurance type. There was no difference in sex, income level, facility type, primary tumor location, tumor grade, and TNM classification in the unmatched groups (Table 1) .
Factors Predicting Receipt of PCI
In multivariable logistic regression analysis, independent factors that predicted for no PCI included race (black vs. white: odds ratio
[OR], 0.55; P ¼ .01), age (age 75 vs. age < 65: OR, 0.65; P ¼ .003), and CharlsoneDeyo comorbidity score (score of 1 vs. 0: OR, 0.76; P ¼ .006; Table 2 ).
Effect of PCI on Overall Survival
In multivariable Cox proportional hazards analysis of the unmatched cohort of patients with a minimum survival of 6 months, treatment with PCI was associated with a significant OS benefit compared with the no PCI cohort (hazard ratio, 0.66; 95% confidence interval, 0.60-0.74; P < .0001). Other factors significantly associated with OS included age, sex, race, CharlsoneDeyo comorbidity score, income, T classification, nodal status, and M classification ( Table 3) .
Effect of PCI on Overall Survival in the Propensity Score-Matched Cohort
To account for potential biases favoring the receipt of PCI in patients with more favorable prognoses, we conducted 1:1 propensity score-matched survival analyses. In the matched cohort with a minimum survival of 6 months, there were a total of 472 patients in each arm (chemotherapy with or without PCI). Baseline characteristics of the matched patients were well balanced across all Figure 2A ). On subset analysis, receipt of PCI was associated with a significant survival benefit in all patients except for those 75 years of age and older and patients with N0-1 or M1a disease (see Supplemental Table 1 in the online version).
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To minimize bias, the initial analysis only included patients who survived at least 6 months from diagnosis in an attempt to eliminate those who likely did not respond to or relapsed quickly after firstline chemotherapy, and thus would have never been offered PCI. To further minimize bias and to confirm a survival benefit to PCI, a similar analysis was performed for patients with a minimum OS of 9 months. After applying this exclusion criterion, 396 patients (13.8%) received PCI, whereas 2465 patients (86.2%) received only chemotherapy without PCI. These patients had baseline characteristics and predictors of receiving PCI similar to what we previously described (see Supplemental Tables 2 and 3 in the online version). After propensity score-matching, there were 395 patients in each arm and the groups were well balanced (see Supplemental Table 2 in the online version). Importantly, a propensity scorematched survival analysis again showed a survival benefit for PCI. Specifically, with a median follow-up of 29.9 months, PCI led to an improvement in median survival (15.3 months vs. 12.9 months; P < .0001), 1-year OS (71.4% vs. 59.5%; P < .0001), and 2-year OS (23.1% vs. 15.9%; P < .0001; Table 4, Figure 2B ). When we conducted the analysis on the entire cohort without a minimum survival cutoff, the median OS was 13.6 months in the PCI group versus 8.6 months in the no-PCI group (P < .0001).
Discussion
In this study, we analyzed the survival outcomes of patients with metastatic SCLC treated with or without PCI using the NCDB. To our knowledge, this represents the largest retrospective study to date on the efficacy of PCI in this patient population. We identified 4257 patients with metastatic SCLC without brain metastases and a minimum survival of at least 6 months treated from 2010 to 2012. After propensity score-matching with a median follow-up of 30.4 months, we found that PCI was associated with a significant survival benefit with an improvement in median survival of 13.9 versus 11.1 months. We saw a similar survival benefit even when excluding patients who survived < 9 months and when analyzing the entire cohort without a minimum survival cutoff. Additionally, we identified younger age, lower CharlsoneDeyo score, and Caucasian race as factors associated with receipt of PCI.
Although firmly established in the care of patients with limitedstage SCLC who respond to initial therapy, the use of PCI remains controversial for patients with ES disease. The controversy stems from conflicting reports from prospective clinical trials. The 
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meta-analysis by Auperin et al first suggested a survival benefit for PCI on the basis of an analysis that included patients with limitedas well as ES disease who had a complete response to therapy. 8 This finding was confirmed with an additional pooled analysis, which also showed an OS benefit to PCI in limited as well as ES disease. 15 More recently, a phase III trial from the European
Organization for Research and Treatment of Cancer (EORTC)
showed that use of PCI in patients with a partial or complete response to chemotherapy resulted in an improvement in OS and a decrease in brain metastases. However, this trial did not routinely screen patients with a brain MRI scan before PCI. 10 Takahashi and colleagues conducted a similar phase III trial randomizing ES-SCLC patients to PCI versus no PCI, but notably required a screening brain MRI scan before enrollment. Inclusion criteria in this study included ES-SCLC patients with any response to chemotherapy, MRI scan of the brain negative for metastases, and an estimated life expectancy > 3 months. Patients had an MRI scan of the brain at 3-month intervals up to 12 months and at 18 and 24 months after enrollment. Results from this trial showed an improvement in control of brain metastases, but there was no survival benefit, and the trial was stopped early at a planned interim analysis showing futility of PCI. 11 Despite these conflicting data, PCI for patients with ES-SCLC with a good performance status and a response to chemotherapy has a category 2A recommendation from the NCCN. 3 Recent studies surveying US and Canadian radiation oncologists show that the most (98%) of those surveyed recommend PCI in patients with ES-SCLC after a good response to initial therapy. 16, 17 Patients and physicians are understandably concerned about the potential toxicities of PCI. Acute toxicities include alopecia, fatigue, headaches, nausea, and vomiting. Long-term toxicities range from memory loss to neurocognitive dysfunction. In the EORTC randomized trial, Slotman et al assessed the effect of PCI on health-related quality of life (HRQOL). Despite a lower risk of symptomatic brain metastases, PCI had a negative effect on a variety of short-term HRQOL outcomes. 18 However, other trials have not shown a difference in neurocognitive outcomes in comparisons of PCI with observation. 19, 20 Unfortunately, toxicity data are not collected in the NCDB, but there are a variety of studies investigating reducing these toxicities, such as hippocampal-sparing intensity-modulated radiation therapy 21 and memantine. 22 The survival outcomes in our study follow trends similar to those in the EORTC trial that showed a benefit for PCI (6.7 vs. 5.4 months; P ¼ .003). 10 However, the absolute numbers are more comparable with those observed in the recent Japanese trial (11.6 vs. 13.7 months, P ¼ .091). 11 The overall improvement in survival is likely because of the shared, more recent time period (post 2009) for our cohort as well as the Japanese study, whereas the EORTC trial enrolled patients from 2001 to 2006. The more widespread use of positron emission tomography staging over the past decade might also have led to stage migration and favorably shifted the overall outcomes.
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Our study also highlights potentially important health care disparities with patients of older age (age 75 years or older vs. age younger than 65 years: OR, 0.65; P ¼ .003), more comorbidities (CharlsoneDeyo score 1 vs. 0: OR, 0.76; P ¼ .006), and black race (black vs. white: OR, 0.55; P ¼ .01) less likely to receive treatment with PCI. It is understandable why a physician would not recommend PCI because of patient age and performance status for medical concerns. However, the racial disparities we found are more concerning. Although we recognize that our findings are subject to biases associated with retrospective and large database studies, these disparities are consistent with published data showing oncologic treatment inequities according to race. 24, 25 In particular, disparities have previously been assessed in patients with lung cancer in studies that have indicated that black men have a higher incidence of lung cancer in the United States as well as higher cancer-related mortality compared with white men. 1, 24 These findings suggest that racial inequities in treatment recommendations, including the receipt of 
OS) of (A) 6 Months and (B) 9 Months
Abbreviation: PCI ¼ prophylactic cranial irradiation.
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PCI that was found in our study, might contribute to worse clinical outcomes for black patients, and providing equal access to health care might help eliminate these disparities. 26 Furthermore, this study highlights the general lack of use of PCI in US cancer centers, where only 11% of our population was treated with PCI. This low statistic is surprising because most US and Canadian radiation oncologists would recommend PCI for patients with ES-SCLC after a response to chemotherapy. 16, 17 However, this was before the publication of the prospective trial by Takahashi et al.
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This study has several important limitations. As with any retrospective analysis, certain unknown biases might exist that cannot be controlled for and could influence the results. Most notably, the data in the NCDB do not indicate why certain patients did not receive PCI. It is possible that some patients progressed through initial chemotherapy, relapsed quickly after systemic treatment, or had a poor performance status precluding treatment with PCI. To minimize these biases, we performed a propensity score-matched analysis before comparing survival outcomes. Moreover, to account for additional biases in the receipt of PCI, we excluded patients with an OS < 6 months to eliminate those who likely did not respond to or relapsed quickly after first-line chemotherapy, and thus would have never been offered PCI. We extended our propensity score-matched analysis to those with a minimum survival of 9 months to further minimize these biases and continued to observe similar trends in OS.
Another, limitation to our study is that the NCDB does not distinguish between the radiation treatment intent, namely PCI versus therapeutic WBRT. To overcome this limitation, we included only patients without brain metastases and categorized PCI as those who received intracranial radiation doses < 30 Gy and 20 Gy. This dose range includes the 2 doses recommended by the NCCN, including 25 Gy in 10 fractions or 20 Gy in 10 fractions. Furthermore, this dose range fits with recent survey data that suggest that most radiation oncologists favor 25 Gy as the PCI dose. 17 Any patient treated with a radiation dose of 30 Gy was omitted from the analysis because such doses are more typical of therapeutic radiation for known brain metastases. We were also unable to analyze the effect of consolidative thoracic radiation on outcomes because the NCDB lists only 1 course of radiation per patient, and more specifically the highest radiation dose received. The use of consolidative thoracic radiotherapy was probably low, however, during our study period (2010-2012) because this was before the publication of randomized trial data showing the benefit of thoracic radiotherapy in ES-SCLC. 27 Last, the fact that only 11.1% of our population received PCI is surprisingly low and possibly indicative of bias in this study. One hypothesis is that these low numbers might be a result of our decision to omit from the analysis patients receiving 30 Gy of radiation. Although this higher dose is usually more indicative of therapeutic WBRT, it is certainly an option for PCI, and, therefore, we might have eliminated some patients who received PCI.
Conclusion
This retrospective cohort study further supports the benefits of PCI in patients with ES-SCLC who respond to initial chemotherapy. On the basis of the results of this large, modern, population-based study, PCI might offer a significant OS benefit in the appropriately selected ES-SCLC patient. Further prospective, randomized trials are needed to reconcile divergent reports of the clinical effect of PCI on survival and further guide the management of these patients.
Clinical Practice Points
Patients diagnosed with SCLC have a high propensity to develop brain metastases. As such, those who respond to initial chemotherapy without developing brain metastases are often treated with PCI to target any microscopic intracranial disease. Prophylactic cranial irradiation is well established in the care of patients with limited stage disease; however, its role in the treatment of patients with extensive stage disease is more controversial, with conflicting evidence from prospective randomized trials. The aim of this study was to determine the effect of PCI on OS in patients with metastatic SCLC who were treated with initial chemotherapy.
To address this question, we used the NCDB. After a propensity score-matched analysis there was a significant survival benefit for patients who received PCI, with a median survival of 13.9 versus 11.1 months (P < .0001), 1-year OS of 61.2% versus 44.0% (P < .0001), and 2-year OS of 19.8% versus 11.5% (P < .0001). Overall, this retrospective study, which is the largest in this population to date, shows that patients with metastatic SCLC treated with PCI have significantly improved survival outcomes. In light of conflicting results from randomized trials on the role of PCI in ES-SCLC, this study adds clinically important information to help guide physician and patient decision-making about the utility of PCI in metastatic SCLC.
Acknowledgments
Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number KL2TR001879. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
The data used in this study were derived from a deidentified NCDB file. The American College of Surgeons and the CoC have not verified and are not responsible for the analytical and statistical methodology used or the conclusions drawn from these data by the investigators. The interpretation and reporting of these data are the sole responsibility of the authors.
Disclosure
The authors have stated that they have no conflicts of interest.
Supplemental Data
Supplemental tables accompanying this article can be found in the online version at https://doi.org/10.1016/j.cllc.2017.12.003.
Prophylactic Cranial Irradiation in Metastatic SCLC
-Clinical Lung Cancer May 2018
Supplemental 
Sonam Sharma et al
Clinical Lung Cancer May 2018 -269.e2
